ReviewThe British journal of radiology2019
Expanding the therapeutic index of radiation therapy by normal tissue protection.
Review in The British journal of radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 71 citations in OpenAlex.
- Oral 5-aminolevulinic Acid for Patients With Localized Prostate Cancer Undergoing Low-dose-rate Brachytherapy: AMBER Trial.In vivo (Athens, Greece)Trial
- Gold Nanoparticle-Mediated DNA Damage Under FLASH Electron-Beam Irradiation: A Monte Carlo Study.Nanomaterials (Basel, Switzerland) · 2026Article
- Quantifying the therapeutic index of acupoints using measurements of effective and hazardous depths.Integrative medicine research · 2026Article
- Integrin α2: mode of regulation and functioning in the metastatic cancer cascade.Journal of translational medicine · 2026Review
- FLASH Radiotherapy Enhances the Therapeutic Ratio in an Embryonic In Vivo Model of Pancreatic Carcinoma.ACS applied materials & interfaces · 2025Article
- The glycolytic enzyme PGK1 phosphorylates MORC2 to Confer radioresistance in pancreatic ductal adenocarcinoma.Cell death & disease · 2025Article
- Cellular Mechanisms of Photobiomodulation in Relation to HeLa Kyoto Tumor Cells Exposed to Ionizing Radiation.International journal of molecular sciences · 2025Article
- Beam intensity and stability control on a modified clinical linear accelerator for FLASH irradiation.Physics in medicine and biology · 2025Article
- Evaluation of antigen agnostic anti-tumor activity and immune memory induced by CBX-15 (alphalexImmunotherapy · 2025Article
- Inflammatory signatures across four photon radiotherapy and proton radiotherapy: mechanisms, mitigation, and quality of life impact.Exploration of targeted anti-tumor therapy · 2025Review
- FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?Seminars in radiation oncology · 2024Review
- Ferroptosis: Frenemy of Radiotherapy.International journal of molecular sciences · 2024Review
- Direct Measurements of FLASH-Induced Changes in Intracellular Oxygenation.International journal of radiation oncology, biology, physics · 2024Article
- Article
- Microarray analysis identifies coding and non-coding RNA markers of liver injury in whole body irradiated mice.Scientific reports · 2023Article
- Key changes in the future clinical application of ultra-high dose rate radiotherapy.Frontiers in oncology · 2023Article
- Review
- Review
- Potential Molecular Mechanisms behind the Ultra-High Dose Rate "FLASH" Effect.International journal of molecular sciences · 2022Review
- Ultrafast Tracking of Oxygen Dynamics During Proton FLASH.International journal of radiation oncology, biology, physics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Normal tissue damages induced by radiation therapy remain dose-limiting factors in radiation oncology and this is still true despite recent advances in treatment planning and delivery of image-guided radiation therapy. Additionally, as the number of long-term cancer survivors increases, unacceptable complications emerge and dramatically reduce the patients' quality of life. This means that patients and clinicians expect discovery of new options for the therapeutic management of radiation-induced complications. Over the past four decades, research has enhanced our understanding of the pathophysiological, cellular and molecular processes governing normal tissue toxicity. Those processes are complex and involve the cross-talk between the various cells of a tissue, including fibroblasts, endothelial, immune and epithelial cells as well as soluble paracrine factors including growth factors and proteases. We will review the translatable pharmacological approaches that have been developed to prevent, mitigate, or reverse radiation injuries based upon the targeting of cellular and signalling pathways. We will summarize the different steps of the research strategy, from the definition of initial biological hypotheses to preclinical studies and clinical translation. We will also see how novel research and therapeutic hypotheses emerge along the way as well as briefly highlight innovative approaches based upon novel radiotherapy delivery procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.